2018 NASH-TAG CONFERENCE
PRESENTATION SLIDES
Click the presentation titles to view and download the accompanying slide deck as a PDF
FRIDAY, JANUARY 5, 2018
SESSION 1: LATEST CLINICAL TRIAL RESULTS
Presenter: Arun Sanyal, MD
Presenter: Stephen Harrison, MD
SESSION 2: CLINICAL TRIAL DESIGN UPDATES
Optimizing Prescreen Strategies to Minimize Screen Failures
Presenter: Stephen Harrison, MD
Presenter: Mary Rinella, MD
Combination Strategies: Scientific and Regulatory Challenges
Presenter: William Symods, PharmD
Proposal for a Platform NASH Trial: What Is to Gain from It and How to Do It
Presenter: Gary Meininger, MD
SESSION 3: EXPERIMENTAL SESSION
Mediators of Insulin Resistance and Organ Cross Talk
Presenter: Gerry Shulman, MD, PhD
Presenter: Jerry Colca, PhD
Lipotoxicity as a Trigger for
Liver Damage
Presenter: Harmeet Malhi, MD
SATURDAY, JANUARY 6, 2018
SESSION 1: TREATING THE
CIRRHOTIC PATIENT
SESSION 2: NEW PHARMACOLOGICAL
TARGETS
Natural History and Prognosis Landmarks in the Cirrhotic Patient
Presenter: Guadalupe Garcia-Tsao, MD
Outcomes for Trials in the Cirrhotic Patient
Presenter: Arun Sanyal, MD
Pharmacotherapy for Portal Hypertension and Its Impact on Cirrhosis Progression
Presenter: Juan Gonzales-Abraldes, MD
The Modulation of Intestinal Barrier and Bacterial Translocation
Presenter: Gene Chang, MD
Specifics of Cirrhotic Trials and
Their Objectives
Presenter: Jason Campagna, MD, PhD
Presenter: Edgar D. Charles, MD
Presenter: Chimweike Ukomadu, MD, PhD
Presenter: Christopher Chapman, MD
SESSION 3: HEPATIC FIBROSIS: EXPERIMENTAL ADVANCES AND TARGETS FOR THERAPY
Beyond Staging: How to Pick up an Antifibroticsignal at the Gene Expression, Cellular Tissue Level?
Presenter: Scott Friedman, MD
Emerging Strategies for Direct Antifibrotics
Presenter: Yuri Popov, MD
MRE State of the Art for Practice and Clinical Trials
Presenter: Richard Ehman, MD